穿皮冠状动脉干预与冠状动脉旁路移植在左心室缩功能障碍患者中:系统性审查和元分析
Vikash Jaiswal1,2, Song Peng Ang3, Abhigan Babu Shrestha4
1JCCR Cardiology Research, Varanasi.
Annals of medicine and surgery (2012)
|June 26, 2023
概括
冠状动脉旁路移植 (CABG) 优于皮肤冠状动脉干预 (PCI) 在患有缺血左心室缩功能障碍 (LVSD) 的患者中. 在LVSD患者中,CABG可降低死亡,重复手术和心肌梗塞的风险.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 心脏外科手术 心脏外科手术
背景情况:
- 目前的指导方针支持冠状动脉旁路移植 (CABG) 而不是医疗治疗.
- 对于患有缺血性左心室缩功能障碍 (LVSD) 的患者来说,最佳的重血管化策略仍在研究中.
- 在LVSD患者中,只有有限的数据比较了CABG和皮肤冠状动脉干预 (PCI).
研究的目的:
- 在LVSD患者中评估和比较PCI与CABG的临床结果.
- 根据现有的文献来确定LVSD患者最佳的复血管化策略.
主要方法:
- 在PubMed,Embase,Scopus和Cochrane图书馆进行系统的文献搜索,直到2022年11月.
- 对10项研究的元分析,包括13,324名LVSD患者.
- 结果以合并的赔率比率 (OR) 报告,其中使用STATA的95%置信区间 (CI).
主要成果:
- 与CABG相比,PCI组的全因死亡率 (OR 1.15,P=0.03),重复血管化 (OR 3.57,P<0.001) 和心肌梗塞 (MI) (OR 1.92,P=0.048) 的几率较高.
- 心血管死亡率,中风,主要心血管和脑血管不良事件以及心室动脉冲动的发生率在PCI和CABG之间是可比的.
- 平均随访时间为3.75年;常见的并发症包括高血压和糖尿病.
结论:
- 冠状动脉旁路移植 (CABG) 在患有左心室缩功能障碍 (LVSD) 的患者中表现出优于皮肤冠状动脉干预 (PCI) 的优势.
- 在LVSD患者中,CABG与全因死亡,重复血管化和心肌梗塞的风险显著降低.
- 这些发现支持CABG作为LVSD患者首选的再血管化策略.
相关概念视频
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...